THALIDOMIDE USE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A RETROSPECTIVE EVALUATION OF THE PATIENTS
EHA Learning Center, Mehmet Baysal, 215367
DIAGNOSIS AND MANAGEMENT OF ACQUIRED VON WILLEBRAND DISEASE. A SINGLE CENTER EXPERIENCE
EHA Learning Center, Cristina Santoro, 215368
CONGENITAL FXIII DEFICIENCY IN PAKISTAN
EHA Learning Center, Munira Borhany, 215369
DISSEMINATED INTRAVASCULAR COAGULATION SCORING IN CHILDREN WITH ACUTE LEUKEMIA: IS THERE A SIMPLER AND ECONOMICAL ALTERNATIVE?
EHA Learning Center, Yasmine El Chazli, 215370
EFFECT OF THROMBOELASTOGRAPHY DEFINED COAGULOPATHY IN TRAUMATIC BRAIN INJURY
EHA Learning Center, DIBYENDU DE, 215371
ASSESSMENT AT DIAGNOSIS OF 200 PATIENTS WITH A PNH CLONE OR GPI-DEFICIENT CELLS ≥0.01% ENROLLED IN A NATION-WIDE MULTICENTRIC PROSPECTIVE OBSERVATIONAL STUDY
EHA Learning Center, Orianne Wagner-Ballon, 215372
ASSOCIATION OF AUTOPHAGY-RELATED GENE 5 VARIANTS WITH ACQUIRED APLASTIC ANEMIA IN HAN-CHINESE POPULATION
EHA Learning Center, Yahong You, 215373
PHASE IB STUDY OF THE CXCR4 ANTAGONIST BL8040 COMBINED WITH IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH APLASTIC ANEMIA
EHA Learning Center, Tapan Kadia, 215374
CLINICAL EFFICACY OF THERAPIES FOR TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A RETROSPECTIVE COHORT STUDY IN MULTIPLE HOSPITALS
EHA Learning Center, Guangsheng He, 215375
IDIOPATHIC NEUTROPENIA OF INFANCY: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY
EHA Learning Center, Piero Farruggia, 215376
DYNAMICS OF CMV AND EBV LOADS AFTER IMMUNOSUPPRESSIVE TREATMENT WITH RABBIT ATG AND CYCLOSPORINE IN ADULT APLASTIC ANEMIA: A PROSPECTIVE OBSERVATIONAL STUDY
EHA Learning Center, Jong Wook Lee, 215377
PHASE 2 STUDY OF X4P-001: A TARGETED ORAL THERAPY FOR PATIENTS WITH WHIM SYNDROME
EHA Learning Center, David Dale, 215378
SCREENING FOR TELOMERE DISEASE IS IMPORTANT TO IMPROVE THE OUTCOME OF HSCT IN PEDIATRIC PATIENTS SUFFERING FROM SEVERE APLASTIC ANEMIA.
EHA Learning Center, Iris Nederlof, 215379
RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN CONGENITAL BONE MARROW FAILURE SYNDROMES: SINGLE CENTER EXPERIENCE WITH FOCUS ON TCR ΑΒ+/CD19+ DEPLETION
EHA Learning Center, Zhanna Shekhovtsova, 215380
REACTIVATION OF HEPATITIS B VIRUS INFECTION IN APLASTIC ANEMIA PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY
EHA Learning Center, Guangsheng He, 215381
ADULT PATIENTS WITH ACQUIRED PURE RED CELL APLASIA: COMBINATION OF CYCLOSPORINE A AND CORTICOSTEROIDS PRODUCE BETTER CR
EHA Learning Center, Guangsheng He, 215382
MANAGEMENT OF PATIENTS WITH SEVERE APLASTIC ANAEMIA WHO ARE REFRACTORY TO PLATELET TRANSFUSIONS USING LEUKOCYTE CONCENTRATES
EHA Learning Center, jiali Huo, 215383
IRON OVERLOAD AND MANAGEMENT IN PATIENTS WITH DIAMOND BLACKFAN ANEMIA
EHA Learning Center, Sule Unal, 215384
HIGHER RATE OF DYSMORPHIC FEATURES IN PATIENTS WITH DIAMOND BLACKFAN ANEMIA
EHA Learning Center, Sule Unal, 215385
OPTIMIZING MRD RESPONSE ASSESSMENT USING HIGH-SENSITIVITY PERIPHERAL BLOOD MONITORING DURING TREATMENT WITH IBRUTINIB COMBINED WITH OBINUTUZUMAB OR VENETOCLAX IN CLL .
EHA Learning Center, Andy C. Rawstron, 215386
DYNAMIC OF TELOMERIC PARAMETERS IN RELAPSING OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AN ANALYSIS OF THE FILO ICLL001 BOMP TRIAL
EHA Learning Center, laura bounaix, 215387
HIGH CD9 EXPRESSION IS ASSOCIATED WITH THE MYD88 L265P MUTATION AND REDUCED FAILURE-FREE SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Jennifer Brown, 215388
CERDULATINIB SYNERGISES WITH BCL-2 AND MCL-1 INHIBITORS TO INDUCE SUPERIOR CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Andrew J. Steele, 215389
SELECTIVE CHK1 INHIBITOR MU380 EXHIBITS SINGLE-AGENT ACTIVITY AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA CELLS WITH TP53 MUTATIONS
EHA Learning Center, Miroslav Boudny, 215390
PI3K INHIBITORS INHIBIT TUMOR MICROENVIRONMENT (TME) REGULATION OF PROGRAMMED DEATH-1 (PD1) AND PDL1/2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A POTENTIAL APPROACH TO OVERCOME TUMOR-INDUCED TOLERANCE
EHA Learning Center, Fortunato Morabito, 215391
PEMBROLIZUMAB (PEM) ACTIVITY IN CLL IS IMMUNE TO TUMOR MICROENVIRONMENTAL (TME) STIMULI
EHA Learning Center, Fortunato Morabito, 215392
DUAL MTOR KINASE INHIBITORS SYNERGIZE WITH IBRUTINIB TO INDUCE CLL APOPTOSIS, AND OVERCOME BCR- AND STROMAL-MEDIATED SURVIVAL ADVANTAGES CONFERRED IN THE MICROENVIRONMENT
EHA Learning Center, Michael Moles, 215393
DEVELOPMENT OF SELECTIVE CASEIN KINASE 1 DELTA/EPSILON INHIBITORS FOR CANCER THERAPY
EHA Learning Center, Michaela Gregorova, 215394
NEXT-GENERATION SEQUENCING AND CRISPR/CAS9 APPLICATION TO ELUCIDATE THE IMPLICATIONS OF TP53 MUTATIONS IN DEL(13Q) CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Miguel Quijada Alamo, 215396
ENCYCLOPEDIA OF CLL SUBSETS: AN ONLINE KNOWLEDGEBASE FOR SUBSETS OF CLL CASES WITH STEREOTYPED B CELL RECEPTORS
EHA Learning Center, Tomas Reigl, 215397
ANALYSIS OF LOCUS-SPECIFIC LINE-1 AND ALU ELEMENT DNA METHYLATION REVEALS NOVEL EARLY EPIGENETIC CHANGES IN CHRONIC LYMPHOCYTIC LEUKAEMIA
EHA Learning Center, Timothy Barrow, 215398
ILT3/DELTEX-1/SHIP-1 AS A NOVEL INHIBITORY AXIS CONTROLLING B CELL RECEPTOR SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Anna Kabanova, 215399
DETIN: OVERCOMING TUMOR IN NORMAL CONTAMINATION.
EHA Learning Center, Amaro Taylor-Weiner, 215400
TRACKING THE MINOR CLONES IN OLIGOCLONAL CHRONIC LYMPHOCYTIC LEUKEMIA USING HIGH-THROUGHPUT IMMUNOPROFILING
EHA Learning Center, Kamila Stranska, 215401
SINGLE CELL ABNORMALITIES ON CLASSIC G-BANDING ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: A NEW DIAGNOSTIC AND BIOLOGICAL CHALLENGE?
EHA Learning Center, Anastasia Athanasiadou, 215402
HIGHER RESPONSIVENESS OF CLL CELLS TO B-CELL RECEPTOR STIMULATION IS ASSOCIATED WITH REDUCED EXPRESSION OF INHIBITORY MOLECULES OF THE NF-ΚB PATHWAY
EHA Learning Center, Ruud Meijers, 215403
COMPARISON OF CELLULAR AND CELL-FREE DNA FOR THE DETECTION AND MONITORING OF BTK MUTATED CLL CLONES IN PATIENTS WITH SUBSEQUENT THERAPY AFTER IBRUTINIB FAILURE
EHA Learning Center, Wiebke Schier, 215404
NOVEL STRATEGIES OF TARGETING P53 RELATED VULNERABILITIES IN T-PLL CELLS
EHA Learning Center, Jana von Jan, 215405
HIGH SET ALPHA TO SET BETA ISOFORM EXPRESSION IS ASSOCIATED WITH INFERIOR OUTCOMES AND DISCRIMINATES FAVORABLE RISK IN TWO INDEPENDENT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) COHORTS
EHA Learning Center, Danielle Brander, 215406
NOTCH1 MUTATIONS ARE AN INDEPENDENT PROGNOSTIC FACTOR IN IBRUTINIB- TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS
EHA Learning Center, Giovanni DEL POETA, 215407
PROGNOSTIC IMPACT OF POSITIVE MINIMAL RESIDUAL DISEASE (MRD) BELOW THE THRESHOLD OF 0.01% IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS AFTER IMMUNOCHEMOTHERAPY: STUDY OF A DATASET FROM 3 FILO TRIALS
EHA Learning Center, Remi Letestu, 215408
EVALUATION OF THE INCIDENCE, RISK FACTORS, AND MANAGEMENT OF HYPERTENSION IN PATIENTS RECEIVING IBRUTINIB FOR HEMATOLOGIC MALIGNANCIES
EHA Learning Center, Farrukh Awan, 215409
EVALUATION OF THE CLL-IPI IN PREVIOUSLY UNTREATED CLL PATIENTS RECEIVING CHEMO-IMMUNOTHERAPY AS FIRST-LINE TREATMENT: ANALYSIS OF 845 CASES.
EHA Learning Center, Massimo GENTILE, 215410
SPONTANEOUS CLINICAL REGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND BIOLOGIC FEATURES OF 27 NEW CASES FROM THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) INTERNATIONAL REGISTRY
EHA Learning Center, Ilaria Del Giudice, 215411
A PROGNOSTIC TOOL FOR THE IDENTIFICATION OF EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AT IMMINENT RISK OF PROGRESSION
EHA Learning Center, Lodovico Terzi di Bergamo, 215412
SURVIVAL CONTINUES TO INCREASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION-BASED ANALYSIS AMONG 19,131 PATIENTS DIAGNOSED IN THE NETHERLANDS BETWEEN 1989 AND 2015
EHA Learning Center, Lina van der Straten, 215413
PROGNOSTICATION AND FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: A CONTEMPORARY, NATIONWIDE, POPULATION-BASED ANALYSIS AMONG 1,677 PATIENTS DIAGNOSED IN THE NETHERLANDS
EHA Learning Center, Lina van der Straten, 215414
“IMMUNO-FLOW-FISH”: HIGH THROUGHPUT FLUORESCENCE IN SITU HYBRIDISATION OF PHENOTYPED CHRONIC LYMPHOCYTIC LEUKAEMIA BY IMAGING FLOW CYTOMETRY FOR CLINICAL APPLICATION
EHA Learning Center, Wendy Erber, 215415
EXPRESSION OF ANTIGENS INVOLVED IN THE FORMATION OF AN IMMUNOLOGICAL SYNAPSE IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Yulia Davydova, 215416
IDENTIFICATION OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AT HIGH RISK OF INFECTION OR TREATMENT THROUGH MACHINE LEARNING ALGORITHMS
EHA Learning Center, Carsten Niemann, 215417
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN RELATION TO RESPONSE TO FIRSTLINE THERAPY AND SUBSEQUENT TREATMENTS – A METAANALYSIS OF HRQOL MEASURED IN PHASE III TRIALS OF THE GERMAN CLL STUDY GROUP
EHA Learning Center, Nadine Kutsch, 215418
T-LARGE GRANULAR LYMPHOCYTIC (T-LGL) LEUKEMIA: A LONG-TERM STUDY ON 51 PATIENTS-COULD WE CONFINE THE USE OF THE TERM “LEUKEMIA”?
EHA Learning Center, Xanthi Yiakoumis, 215419
FLOW CYTOMETRY AND PCR-BASED T-CELL CLONALITY TESTING FOR DISCRIMINATING BETWEEN REACTIVE AND NEOPLASTIC PROLIFERATION OF LARGE GRANULAR LYMPHOCYTES
EHA Learning Center, Natalia Chernova, 215420
A US BASED SURVEY: THE EXPERIENCES AND PERSPECTIVES OF 1147 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS
EHA Learning Center, Brian Koffman, 215421
CHRONIC LYMPHOCYTIC LEUKEMIA IN ICELAND: A NATION-WIDE EPIDEMIOLOGY STUDY FROM 2003 TO 2016
EHA Learning Center, Hrafn Thorvaldsson, 215422
ENRICHMENT OF ASXL1 PATHOGENIC VARIANTS AMONG PRIMARY REFRACTORY CML PATIENTS
EHA Learning Center, Kristin Gustafsson, 215423
THE PIVOTAL ROLE OF INSULIN-LIKE GROWTH FACTOR PATHWAY AS A THERAPEUTIC TARGET IN ABL TYROSINE KINASE INHIBITOR RESISTANT LEUKEMIA CELLS
EHA Learning Center, Seiichi Okabe, 215424
ASXL1 MUTATIONS ARE FREQUENT IN CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO TYROSINE KINASE INHIBITORS BUT NOT IN PATIENTS WITH OPTIMAL RESPONSE
EHA Learning Center, Marcin MACHNICKI, 215425
THE UNCOVERING OF A BCR-ABL1 TYROSINE KINASE-INDEPENDENT SIGNATURE REVEALS NEW POTENTIAL THERAPEUTIC TARGETS IN CHRONIC MYELOID LEUKAEMIA STEM CELLS
EHA Learning Center, Mhairi Copland, 215426
OPTIMAL TIME POINT FOR BCR-ABL1 KD MUTATION ANALYSIS IN CML PATIENTS; BASED ON 2013 ELN GUIDELINE
EHA Learning Center, Young Rok Do, 215427
CLONAL SELECTION DETERMINES RESULTANT DOMINANCE OF TYROSINE KINASE INHIBITOR-RESISTANT CELLS IN CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Benjamin Leow, 215428
WT1 ANALYSIS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
EHA Learning Center, Sabrina COLUZZI, 215429
DIGITAL DROPLET PCR MAY BETTER IDENTIFY CANDIDATES FOR TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA REGARDLESS OF MEDIAN TREATMENT DURATION
EHA Learning Center, Gioia colafigli, 215430
FREQUENCY OF TYPICAL AND ATYPICAL FUSION TRANSCRIPTS IN PATIENTS WITH BCR-ABL1-POSITIVE LEUKEMIAS – A SINGLE INSTITUTION STUDY
EHA Learning Center, Gueorgui Balatzenko, 215431
PATIENT-SPECIFIC BCR-ABL1 GENOMIC FUSION ANALYSIS OF MINIMAL RESIDUAL DISEASE OF CML PATIENTS ELIGIBLE FOR TKI STOPPING SIGNIFICANTLY OUTPERFORMED MRNA DETECTION EITHER BY QPCR OR DIGITAL PCR
EHA Learning Center, Katerina Machova Polakova, 215432
TREATMENT-FREE REMISSION AFTER SECOND-STOP OF IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
EHA Learning Center, Sukjoong Oh, 215433
TWO YEARS OF THERAPY WITH MATINIB GENERICS IN CHRONIC MYELOID LEUKEMIA; A REPORT FROM THE POLISH ADULT LEUKEMIA GROUP (PALG) IMATINIB GENERICS REGISTRY
EHA Learning Center, Tomasz , 215434
MAINTENANCE THERAPY WITH DASATINIB ADMINISTRATED EVERY OTHER DAY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Clemence Loiseau, 215435
PONATINIB 15 MG DAILY, COMBINING EFFICACY AND TOLERABILITY. A RETROSPECTIVE SURVEY IN ITALY.
EHA Learning Center, Gianni Binotto, 215436
THE EUTOS LONG-TERM SURVIVAL SCORE PREDICTS RESPONSE AND SURVIVAL OF ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS BETTER THAN SOKAL SCORE
EHA Learning Center, Fausto Castagnetti, 215437
CARDIOVASCULAR TOXICITY IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS IN REAL-LIFE PRACTICE. IDENTIFICATION OF RISK FACTORS AND ROLE OF PROPHYLAXIS
EHA Learning Center, Giovanni Caocci, 215438
ULTRA-SENSITIVE DETECTION OF TYROSINE KINASE INHIBITOR RESISTANT MUTATIONS IN CHRONIC MYELOID LEUKEMIA PATIENTS USING MISEQ ILLUMINA NEXT GENERATION SEQUENCING PLATFORM
EHA Learning Center, Marianna Romžová, 215439
PEG-INTERFERON ΑLPHA 2B CAN IMPROVE MOLECULAR RECURRENCES IN THE TREATMENT-FREE REMISSION; A PILOT STUDY WITH 18-MONTH FOLLOW-UP
EHA Learning Center, Manuel Ayala, 215440
CROSS-INTOLERANCE WITH BOSUTINIB AFTER PRIOR TYROSINE KINASE INHIBITORS IN PATIENTS WITH PHILADELPHIA CHROMOSOME–POSITIVE LEUKEMIA: PHASE 1/2 STUDY UPDATE
EHA Learning Center, Jorge Cortes, 215441
CHRONIC MYELOID LEUKEMIA ITALIAN MULTICENTER OBSERVATIONAL STUDY (CML-IT-MOS): ANALYSIS OF CLINICAL CHARACTERISTICS OF 1330 CML PATIENTS TREATED IN REAL-LIFE IN 66 ITALIAN CENTERS OF THE GIMEMA GROUP
EHA Learning Center, Giorgina Specchia, 215442
IMATINIB STOP STUDY FEASIBLE TO JAPANESE CLINICAL SETTING.
EHA Learning Center, Kensuke Usuki, 215443
THE TARGET UK STUDY: AN EVALUATION OF TYROSINE KINASE INHIBITOR RESPONSE MONITORING PATTERNS AND REAL-WORLD MOLECULAR RESPONSE RATES IN UK PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Adam Mead, 215444
THE OCCURRENCE AND SURVIVAL OF COLD AGGLUTININ DISEASE IN DENMARK
EHA Learning Center, Sigbjørn Berentsen, 215445
DENSITY, HETEROGENEITY AND DEFORMABILITY OF RED CELLS AS MARKERS OF CLINICAL SEVERITY IN HEREDITARY SPHEROCYTOSIS
EHA Learning Center, Richard van Wijk, 215446
LONG-TERM TREATMENT RESPONSE BASED ON SEVERITY OF GAUCHER DISEASE TYPE 1 AT BASELINE IN TREATMENT-NAÏVE ADULT PATIENTS AFTER 8 YEARS OF TREATMENT WITH ORAL ELIGLUSTAT
EHA Learning Center, Elena Lukina, 215448
COMBINED EMA-BINDING TEST AND OSMOTIC GRADIANT EKTACYTOMETRY SIGNIFICANTLY IMPROVE THE LABORATORY DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS
EHA Learning Center, Andreas Glenthøj, 215449
PREVALENCE AND PREDICTORS OF LIVER FIBROSIS EVALUATED BY VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY (FIBROSCAN®) IN ADULT PATIENTS WITH TYPE 1 GAUCHER DISEASE
EHA Learning Center, Maria Domenica Cappellini, 215450
PREVALENCE AND CLINICAL SIGNIFICANCE OF SMALL PNH CLONES IN PATIENTS WITH PRIMARY AUTOIMMUNE HEMOLYTIC ANEMIA
EHA Learning Center, Bruno Fattizzo, 215451
COMBINATION TREATMENT OF RITUXIMAB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOR WARM AUTOIMMUNE HEMOLYTIC ANEMIA
EHA Learning Center, Caroline Piatek, 215452
THE ESTABLISHMENT OF SD RAT MODEL AND HISTOPATHOLOGICAL STUDY OF IMMUNE HEMOLYTIC DISEASE INDUCED BY ANTIBODY.
EHA Learning Center, sai yan, 215453
ALPS AND GAUCHER DISEASE. A CLINICAL AND IMMUNOLOGICAL OVERLAP
EHA Learning Center, Maurizio Miano, 215454
ORGAN INVOLVEMENT IN RARE HEREDITARY HEMOLYTIC ANEMIA
EHA Learning Center, Stephanie van Straaten, 215455
SUCCESSFUL TREATMENT OF MEGALOBLASTIC ANEMIA WITH BONE MARROW MYELODYSPLASIA IN LESCH-NYHAN SYNDROME
EHA Learning Center, Maciej Machaczka, 215456
CORD BLOOD DERIVED GAMMA-DELTA T CELLS CAN BE EXPONENTIALLY EXPANDED IN VITRO TO INDUCE POTENT CYTOTOXICITY AGAINST HUMAN ACUTE MYELOID LEUKEMIA CELLS
EHA Learning Center, Alice Cheung, 215457
SYNERGISTIC ANTITUMORAL EFFICACY OF A NOVEL REPLICATIVE ADENOVIRUS SG611-PDCD5 AND DAUNORUBICIN IN HUMAN LEUKEMIC CELLS
EHA Learning Center, Ya-Lan Zhou, 215458
NOVEL RNA CONSTRUCT INCREASES PERFORIN AND GRANZYME B IN NATURAL KILLER AND CYTOTOXIC T CELLS
EHA Learning Center, Arnika Wagner, 215459
THE REDUCTION OF GRAFT-VERSUS-HOST DISEASE AND TRANSFUSIONAL NEEDS AFTER THE APPLICATION OF MESENCHYMAL STEM CELL THERAPY FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Hajnalka Andrikovics, 215460
IMMUNOGENICITY OF TISAGENLECLEUCEL IN RELAPSED/ REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) AND DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS
EHA Learning Center, Theodore Laetsch, 215461
CONSIDERATIONS FOR TISAGENLECLEUCEL DOSING RATIONALE
EHA Learning Center, Rakesh Awasthi, 215462
MTL-CEBPA, A SMALL ACTIVATING RNA FOR INTRAVENOUS ADMINISTRATION TO ENHANCE C/EBPΑ EXPRESSION IN PATIENTS WITH LIVER CANCER SHOWS POTENTIAL USE IN NEUTROPENIA
EHA Learning Center, Choon Tan, 215463
SIGNIFICANT ARI-0001 (A3B1:CD8:4-1BB:CD3Z CAR19) CELL EXPANSION IN A PATIENT WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PRE-LYMPHOAPHERESIS IBRUTINIB ADMINISTRATION.
EHA Learning Center, Valentín Ortiz-Maldonado Gibson, 215464
HIGH BASELINE FERRITIN IS ASSOCIATED WITH GRADE 2 CRS REQUIRING TOCILIZUMAB OR GRADE ≥ 3 CRS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH BB2121 ANTI-BCMA CAR T CELLS
EHA Learning Center, Jesus Berdeja, 215465
THE COMBINATION OF CD19/BCMA-DIRECTED CART CELLS INDUCED THERAPEUTIC RESPONSE AND REVERSIBLE COMPARTMENTAL CYTOKINE RELEASE SYNDROME CONFINED TO CEREBRAL REGION IN A PATIENT WITH CNS MULTIPLE MYELOMA
EHA Learning Center, Caixia Li, 215466
INITIAL EXPERIENCE IN US COMMERCIAL MANUFACTURING OF TISAGENLECLEUCEL, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR PEDIATRIC RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Brian Majors, 215467
ALLOGENEIC NK CELLS AND THEIR USE IN CLINICAL TRIALS
EHA Learning Center, Ludovit Bielik, 215468

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings